Grundläggande statistik
| LEI | 5493001V8N461H1N6381 |
| CIK | 1642375 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Guardion Health Sciences, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| January 23, 2025 |
As filed with the Securities and Exchange Commission on January 23, 2025 As filed with the Securities and Exchange Commission on January 23, 2025 Registration No. |
|
| January 23, 2025 |
As filed with the Securities and Exchange Commission on January 23, 2025 As filed with the Securities and Exchange Commission on January 23, 2025 Registration No. |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 15-12G 1 form15-12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38861 GUARDION HEALTH SCIENCES, INC. (Exact name |
|
| December 26, 2024 |
Exhibit 10.1 Certain personal information in this document has been redacted pursuant to Item 601(a)(6) of Regulation S-K. Redacted portions are indicated with the notation “[***]”. GENERAL RELEASE AGREEMENT This General Release Agreement (the “Agreement”) is made by and between Guardion Health Sciences, Inc., a Delaware Corporation (the “Company”), and Katie Cox (“Employee”). In consideration for |
|
| December 26, 2024 |
Exhibit 10.2 Certain personal information in this document has been redacted pursuant to Item 601(a)(6) of Regulation S-K. Redacted portions are indicated with the notation “[***]”. CONSULTING AGREEMENT This Consulting Agreement, effective as of January 1, 2025 (this “Agreement”), is by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), with an address at 2925 Rich |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| December 26, 2024 |
Guardion Health Sciences Announces Declaration of Cash Distribution Exhibit 99.1 Guardion Health Sciences Announces Declaration of Cash Distribution HOUSTON, TEXAS – December 23, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash distribution (the “Distribution”) in an amount equal to $3.25 per share of common stock, par value $0.001 per share (the “Common Stock”), held b |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| November 18, 2024 |
Exhibit 3.1 AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED BYLAWS OF GUARDION HEALTH SCIENCES, INC. a Delaware Corporation Pursuant to resolutions of the Board of Directors (the “Board”) of Guardion Health Sciences, Inc. a Delaware corporation (the “Corporation”) adopted at a meeting of the Board held on November 14, 2024 and in accordance with the authority provided to the directors pursuant to A |
|
| November 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40145Q500 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| October 31, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| October 31, 2024 |
Guardion Health Sciences Announces Filing of Certificate of Dissolution Exhibit 99.1 Guardion Health Sciences Announces Filing of Certificate of Dissolution HOUSTON, TEXAS – October 30, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the “Effectiv |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38861 GUARDION HEALTH SCIENCES, INC. The NASDAQ Stock Market LLC (Exact name of Issuer as specified in its charter, and name of the Exchange where security is listed and/or re |
|
| October 3, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS – October 1, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpor |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40145Q500 (CUSIP N |
|
| August 21, 2024 |
Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock Exhibit 99.1 Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock HOUSTON, TEXAS – August 21, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 20 |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| August 14, 2024 |
Guardion Also Provides an Update to Stockholders of Significant Recent Developments Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024 Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS – August 13, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers science-based, clinicall |
|
| August 14, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARDION HEALTH SCIEN |
|
| July 15, 2024 |
Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement and General Release (the “Agreement”) is made by and between Guardion Health Sciences, Inc. (the “Company”) and Craig Sheehan (the “Employee”). In consideration for the execution of this Agreement, and the performance of the terms and conditions set forth herein, Company and Employee (each a “Party” and collectively the “Parties”) agree a |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| June 6, 2024 |
Guardion Health Sciences, Inc. Unaudited Pro Forma Condensed Balance Sheet March 31, 2024 Exhibit 99.2 Guardion Health Sciences, Inc. Unaudited Pro Forma Condensed Balance Sheet March 31, 2024 Pro Forma Guardion (A) Adjusted Guardion Health Pro Forma Health Sciences Adjustments and Eliminations Sciences Inc. Debit Credit Inc. Assets Current assets: Cash and cash equivalents $ 5,605,035 16,975,000 (1) 725,000 $ 21,855,035 Cash held in escrow - 225,000 (8) 225,000 Accounts receivable, ne |
|
| June 6, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-suppo |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 23, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution HOUSTON, TEXAS – May 23, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company t |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Defini |
|
| May 21, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024 Company Estimates the Aggregate Potential Liquidating Distributions to Range from approximately $9.00 to $11.00 per Share if Stockholders Vote to Approve the Sale of |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Defini |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 15, 2024 |
Guardion Health Sciences Announces Exhibit 99.1 Guardion Health Sciences Announces - Financial Results for the Three Months Ended March 31, 2024 - Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special Meeting of Stockholders on May 23, 2024 Board of Directors Urges Stockholders to Vote to Approve the Sale of the Company’s Viactiv Brand an |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Defini |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARDION HEALTH SCIE |
|
| May 6, 2024 |
Guardion Health Sciences, Inc. 690,100 Shares of Common Stock Underlying Previously Issued Warrants Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-278470 Guardion Health Sciences, Inc. 690,100 Shares of Common Stock Underlying Previously Issued Warrants This prospectus relates to the offer and sale by us of 690,100 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants (the “Warrants”) that we issued and sold in February 2022 i |
|
| May 2, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 2, 2024 |
GUARDION HEALTH SCIENCES, INC. 2925 Richmond Avenue, Suite 1200 Houston, Texas 77098 Exhibit 99.1 GUARDION HEALTH SCIENCES, INC. 2925 Richmond Avenue, Suite 1200 Houston, Texas 77098 May 1, 2024 Dear Fellow Stockholders, In less than 4 weeks, stockholders of Guardion Health Sciences, Inc. (“Guardion” or the “Company”) will vote on two critical business proposals to be considered at a Special Meeting of Stockholders to be held on May 23, 2024, as follows: 1. To approve the sale of |
|
| May 1, 2024 |
Guardion Health Sciences, Inc. 2925 Richmond Avenue, Suite 1200 Houston, Texas 77098 Guardion Health Sciences, Inc. 2925 Richmond Avenue, Suite 1200 Houston, Texas 77098 May 1, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Guardion Health Sciences, Inc. Registration Statement on Form S-3 File No. 333-278470 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38861 GUARDIO |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| April 9, 2024 |
Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”), dated effective as of the last date of signature noted on the signature page, is entered into by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), Craig Sheehan (the “Employee” and together with the Company, collectively, the “Parties”). RECITALS WHEREAS, the |
|
| April 9, 2024 |
Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”), dated effective as of the last date of signature noted on the signature page, is entered into by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), Janet Hall (the “Employee” and together with the Company, collectively, the “Parties”). RECITALS WHEREAS, the Emp |
|
| April 9, 2024 |
Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT AND TERMINATION OF RETENTION AGREEMENT This Amendment to Employment Agreement (this “Amendment”), dated effective as of the last date of signature noted on the signature page, is entered into by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), Katie Cox (the “Employee” and together with the Company, collectively, the |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☒ Defini |
|
| April 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) GUARDION HEALTH SCIENCES, INC. |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 2, 2024. As filed with the Securities and Exchange Commission on April 2, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4428421 (State or other jurisdiction (I.R.S. Employer of incorporation o |
|
| April 1, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023 Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS – March 29, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Gua |
|
| April 1, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporatio |
|
| March 29, 2024 |
Guardion Health Sciences, Inc. Clawback Policy Exhibit 97.1 GUARDION HEALTH SCIENCES, INC. COMPENSATION RECOUPMENT POLICY I. Purpose and Scope The Board believes that it is in the best interests of Guardion Health Sciences, Inc. (the “Company”) and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore |
|
| March 29, 2024 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Guardion Health Sciences, Inc. (“the Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)—our common stock, par value $0.001 per share (“Common Stock”). Descripti |
|
| March 29, 2024 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES OF GUARDION HEALTH SCIENCES, INC. Name State or Other Jurisdiction of Incorporation NutriGuard Formulations, Inc. Delaware Viactiv Nutrititionals, Inc. Delaware |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38861 GUARDION HEALTH SCIENCES, |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Defini |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☐ Defini |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 40145Q500 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 5, 2024 |
SC 13G/A 1 ghsi13ga.htm GHSI 13GA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40145Q500 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| January 31, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| January 31, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc. HOUSTON, TEXAS – January 30, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell its Activ Nutritional, LLC subsidiary, which o |
|
| January 31, 2024 |
Exhibit 99.1 Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc. HOUSTON, TEXAS – January 30, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell its Activ Nutritional, LLC subsidiary, which o |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| January 31, 2024 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT BY AND AMONG DOCTOR’S BEST INC., ACTIV NUTRITIONAL, LLC, VIACTIV NUTRITIONALS, INC. AND GUARDION HEALTH SCIENCES, INC. DATED AS OF January 30, 2024 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF UNITS; PURCHASE PRICE 5 1.1 Purchase and Sale of Closing Units 5 1.2 Purchase Price 5 1.3 Closing Payments 5 1.4 Adjustment of the Purchase Price 6 1.5 Withhol |
|
| January 31, 2024 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT BY AND AMONG DOCTOR’S BEST INC., ACTIV NUTRITIONAL, LLC, VIACTIV NUTRITIONALS, INC. AND GUARDION HEALTH SCIENCES, INC. DATED AS OF January 30, 2024 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF UNITS; PURCHASE PRICE 5 1.1 Purchase and Sale of Closing Units 5 1.2 Purchase Price 5 1.3 Closing Payments 5 1.4 Adjustment of the Purchase Price 6 1.5 Withhol |
|
| November 21, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| November 13, 2023 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023 Viactiv® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022 HOUSTON, TEXAS – November 13, 2023 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHS |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARD |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 26, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), and the individual identified on Exhibit A attached hereto (the “Employee”) effective as of the Effective Date (as defined in Exhibit A). RECITALS WHEREAS, the Company is a clinical nutrition and diagnostics company that devel |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpor |
|
| August 14, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| August 14, 2023 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023 Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstrates Positive Results of Company’s Focus on eCommerce Initiatives HOUSTON, TEX |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARDION H |
|
| July 31, 2023 |
Exhibit 10.1 May 18, 2023 Katherine Cox 13777 Tender Drive Carmel, IN 46032 Re: Retention Agreement Dear Katie: Guardion Health Sciences, Inc. (the “Company”) wishes to recognize and reward your contributions to our success and to encourage your active involvement and continued contributions to the Company. Therefore, the Company is pleased to offer you this Retention Agreement (the “Agreement”), |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| June 16, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) GUARDION HEALTH SCIENCES, INC. |
|
| June 16, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 16, 2023 S-8 1 forms-8.htm As filed with the U.S. Securities and Exchange Commission on June 16, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4428421 (State or other jurisdiction of incorporat |
|
| June 5, 2023 |
Exhibit 10.1 June 1, 2023 Craig Sheehan Re: 2023 Bonus Agreement Dear Mr. Sheehan: Guardion Health Sciences, Inc. (the “Company”) wishes to retain the benefits of your experience, expertise and assistance prior to a potential sale of the Viactiv® brand/Activ Nutritional, LLC entity, or “Change of Control”, as defined in the Guardion Health Sciences, Inc. 2018 Omnibus Equity Incentive Plan and to e |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 30, 2023 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer Former President and Chief Executive Officer Bret Scholtes Resigning to Pursue Other Business Opportunies HOUSTON, TEXAS – May 30, 2023 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Com |
|
| May 30, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), and the individual identified on Exhibit A attached hereto (the “Employee”), effective as of the Effective Date (as defined in Exhibit A). RECITALS WHEREAS, the Company is a publicly held and listed specialty health sciences c |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 16, 2023 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023 Viactiv® Product Line Total Revenue Increased approximately 37% for the Quarter Ended March 31, 2023 as compared to the Quarter Ended March 31, 2022 HOUSTON, TEXAS – May 15, 2023 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition c |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARDION |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38861 GUARDIO |
|
| April 20, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporatio |
|
| April 20, 2023 |
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022 EX-99.1 2 ex99-1.htm Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022 HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, heal |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38861 GUARDION HEALTH SCIENCES, |
|
| April 17, 2023 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Guardion Health Sciences, Inc. (“the Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)—our common stock, par value $0.001 per share (“Common Stock”). Descripti |
|
| April 17, 2023 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES OF GUARDION HEALTH SCIENCES, INC. Name State or Other Jurisdiction of Incorporation VectorVision Ocular Health, Inc. Delaware Transcranial Doppler Solutions, Inc. Delaware NutriGuard Formulations, Inc. Delaware Viactiv Nutrititionals, Inc. Delaware |
|
| April 3, 2023 |
NT 10-K 1 formnt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38861 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transi |
|
| March 7, 2023 |
Exhibit 99.1 Guardion Health Sciences Hires Alantra, LLC as its Financial Advisor to Explore Strategic Alternatives to Maximize Stockholder Value Alantra, LLC is an experienced and successful international healthcare investment banking firm HOUSTON, March 6, 2023 (GLOBE NEWSWIRE) - Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| February 8, 2023 |
GHSI / Guardion Health Sciences Inc / Hudson Bay Capital Management LP - GHSI 13G Passive Investment SC 13G 1 ghsi13g.htm GHSI 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40145Q500 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 40145Q401 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 24, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| January 24, 2023 |
GUARDION HEALTH SCIENCES, INC. REGAINS COMPLIANCE WITH NASDAQ CONTINUED LISTING REQUIREMENTS Exhibit 99.1 GUARDION HEALTH SCIENCES, INC. REGAINS COMPLIANCE WITH NASDAQ CONTINUED LISTING REQUIREMENTS HOUSTON, TX. January 24, 2023 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1 |
|
| January 10, 2023 |
GHSI / Guardion Health Sciences Inc / Radoff Bradley Louis Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40145Q500 (CUSIP N |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| January 6, 2023 |
EX-3.1 2 ex3-1.htm Exhibit 3.1 CERTIFICATE OF AMENDMENT to CERTIFICATE OF INCORPORATION of GUARDION HEALTH SCIENCES, INC. GUARDION HEALTH SCIENCES, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Guardion Health Sciences, Inc. The Certificate of Incorpora |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| January 6, 2023 |
Exhibit 99.1 GUARDION HEALTH SCIENCES, INC. ANNOUNCES 1-FOR-50 REVERSE STOCK SPLIT EFFECTIVE ON PRE-MARKET OPENING ON JANUARY 9, 2023 HOUSTON, TX. January 6, 2023 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (?Guardion? or the ?Company?) (NASDAQ: GHSI) announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on January 6, 2023. Co |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 2, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 29, 2022, between Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). Recitals A.????????????The Company |
|
| December 2, 2022 |
Exhibit 10.3 Guardion Health Sciences, Inc. 2925 Richmond Avenue, Suite 1200 Houston, TX 77098 ? November 29, 2022 ? [INVESTOR NAME] [ADDRESS] [ADDRESS] Attn: ]] Email: [] ? Re: Securities Purchase Agreement, dated as of November 29, 2022 (the ?Securities Purchase Agreement?), by and among Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), the undersigned purchaser (the ?Purch |
|
| December 2, 2022 |
Exhibit 99.1 Guardion Health Sciences Announces Pricing of Aggregate $4.75 Million Institutional Private Placement of Series C and Series D Redeemable Preferred Stock HOUSTON, November 29, 2022 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (?Guardion? or the ?Company?) (Nasdaq: GHSI), a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed |
|
| December 2, 2022 |
Exhibit 3.1 GUARDION HEALTH SCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Bret Scholtes, does hereby certify that: 1. He is the Chief Executive Officer of Guardion Health Sciences, Inc., a Delaware corporation (the ?Corporation?). 2. |
|
| December 2, 2022 |
?Exhibit 10.2 ? REGISTRATION RIGHTS AGREEMENT ? This Registration Rights Agreement (this ?Agreement?) is made and entered into as of November 29, 2022, between Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). ? This Agreement is made pursuant to the S |
|
| December 2, 2022 |
Exhibit 3.2 GUARDION HEALTH SCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Bret Scholtes, does hereby certify that: 1. He is the Chief Executive Officer of Guardion Health Sciences, Inc., a Delaware corporation (the ?Corporation?). 2. The Corpora |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 29, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or Other Jurisdiction of Incorporation) (C |
|
| November 30, 2022 |
GHSI / Guardion Health Sciences Inc / Radoff Bradley Louis Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40145Q401 (CUSIP Nu |
|
| November 30, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 30, 2022 with respect to the Common Stock, par value $0.001 per share, of Guardion Health Sciences, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rul |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARD |
|
| November 14, 2022 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2022 Viactiv® Generated Net Revenues of approximately $2.6 Million or 96% of Net Revenues for the Quarter Ended September 30, 2022 Company Announces Program to Evaluate Strategic Alternatives HOUSTON, TEXAS – November 14, 2022 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. |
|
| August 12, 2022 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Quarter Ended June 30, 2022 Viactiv? Product Line contributes to Highest Quarterly Revenue in Company History of approximately $3.275 Million, Shows Significant Revenue Growth from Prior Quarter HOUSTON, TEXAS ? August 11, 2022 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (Nasdaq: GHSI) (?Guardion? or the ?Company?), a |
|
| August 12, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporati |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARDION H |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38861 GUARDION |
|
| May 4, 2022 |
PowerPoint Presentation, dated May 4, 2022 Exhibit 99.1 |
|
| May 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2022 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Guardion Health Sciences, Inc. (?the Company?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?)?our common stock, par value $0.001 per share (?Common Stock?). Descripti |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38861 GUARDION HEALTH SCIENCES, |
|
| March 31, 2022 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES OF GUARDION HEALTH SCIENCES, INC. Name State or Other Jurisdiction of Incorporation VectorVision Ocular Health, Inc. Delaware Transcranial Doppler Solutions, Inc. Delaware NutriGuard Formulations, Inc. Delaware Viactiv Nutrititionals, Inc. Delaware |
|
| February 28, 2022 |
GHSI / Guardion Health Sciences Inc / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardion Health Sciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 40145Q401 (CUSIP Number) February 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 28, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| February 24, 2022 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248895 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 24, 2020) Guardion Health Sciences, Inc. 32,550,000 Units, Each Unit Consisting of One Share of Common Stock, One Series A Warrant to Purchase One share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock 4,450,000 Pre-funded Units, Each Pre-funded |
|
| February 23, 2022 |
Exhibit 4.3 GUARDION HEALTH SCIENCES, INC. PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: February 23, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Roth Capital Partners, LLC or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| February 23, 2022 |
Exhibit 4.1 GUARDION HEALTH SCIENCES, INC. [CLASS A][CLASS B] COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: February [ ], 2022 THIS [CLASS A][CLASS B] COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| February 23, 2022 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT Guardion Health Sciences, Inc. February 18, 2022 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), Guardion Health Sciences, Inc., a Delaware corporation (the ?Com |
|
| February 23, 2022 |
Guardion Health Sciences, Inc. Announces Pricing of $11 Million Public Offering Exhibit 99.2 Guardion Health Sciences, Inc. Announces Pricing of $11 Million Public Offering HOUSTON, TEXAS, Feb. 18, 2022 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (NASDAQ:GHSI) (?Guardion? or the ?Company?), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, today announced the pricing of a previously announced public offering of 37 |
|
| February 23, 2022 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GUARDION HEALTH SCIENCES, inc. Warrant Shares: Initial Exercise Date: February , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant? and together with each other Pre-Funded Common Stock Purchase Warrant, the ?Warrants?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the |
|
| February 23, 2022 |
Guardion Health Sciences, Inc. Announces Closing of $11 Million Public Offering Exhibit 99.3 Guardion Health Sciences, Inc. Announces Closing of $11 Million Public Offering HOUSTON, TEXAS, Feb. 23, 2022 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (NASDAQ:GHSI) (?Guardion? or the ?Company?), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, today announced the closing of a previously announced public offering of 37 |
|
| February 23, 2022 |
Exhibit 4.4 Guardion Health Sciences, Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agent Agreement Dated as of February 18, 2022 1 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT, dated as of February 18, 2022 (?Agreement?), between Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), and VStock Transfer, LLC (the ?Warrant Agent?). W I T N E S S E T H WHEREAS, pursuan |
|
| February 23, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 18, 2022, between Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and |
|
| February 23, 2022 |
Guardion Health Sciences, Inc. Announces Proposed Public Offering Exhibit 99.1 Guardion Health Sciences, Inc. Announces Proposed Public Offering HOUSTON, TEXAS, February 17, 2022 ? Guardion Health Sciences, Inc. (NASDAQ:GHSI) (?Guardion? or the ?Company?), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, today announced that it intends to offer and sell, shares of its common stock (or common stock equival |
|
| February 22, 2022 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248895 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus Dated September 24, 2020) Guardion Health Sciences, Inc. 32,550,000 Units, Each Unit Consisting of One Share of Common Stock, One Series A Warrant to Purchase One share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock 4,450,000 Pre-funded Units, Each |
|
| February 17, 2022 |
SUBJECT TO COMPLETION, DATED FEBRUARY 17, 2022 Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248895 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus |
|
| February 14, 2022 |
Exhibit 3.1 AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED BYLAWS OF GUARDION HEALTH SCIENCES, INC. a Delaware Corporation Pursuant to resolutions of the Board of Directors (the ?Board?) of Guardion Health Sciences, Inc., a Delaware corporation (the ?Corporation?) adopted at a meeting of the Board held on February 12, 2022 and in accordance with the authority provided to the directors pursuant to |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpora |
|
| January 28, 2022 |
Guardion Health Sciences, Inc. Up to $25,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248895 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 24, 2020) Guardion Health Sciences, Inc. Up to $25,000,000 Common Stock We have entered into an equity distribution agreement (the ?Sales Agreement?) with Maxim Group LLC (?Maxim?) and Roth Capital Partners, LLC (?Roth?, or collectively with Maxim, the ?Distribution Agents?), |
|
| January 28, 2022 |
Exhibit 1.1 Guardion Health Sciences, Inc. Shares of Common Stock (par value $0.001 per share) Equity Distribution Agreement January 28, 2022 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Roth Capital Partners, LLC 888 San Clemente Dr. Newport Beach CA, 92660 Ladies and Gentlemen: Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell th |
|
| January 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| January 27, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| January 12, 2022 |
PowerPoint Presentation, dated January 2022 Exhibit 99.1 |
|
| January 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorpor |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporat |
|
| January 10, 2022 |
PowerPoint Presentation, dated January 2022 Exhibit 99.1 |
|
| December 27, 2021 |
Exhibit 99.1 Guardion Health Sciences to Wind Down VectorVision Business Operations and Focus on Exploiting VectorVision Intellectual Property Management Anticipates $300,000+ Reduction in Annual Operating Costs HOUSTON, TEXAS ? December 23, 2021 ? Guardion Health Sciences, Inc. (?Guardion? or the ?Company?) (Nasdaq: GHSI), a clinical nutrition company that develops clinically supported nutrition, |
|
| December 27, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorpora |
|
| December 17, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorpora |
|
| December 17, 2021 |
Guardion Health Sciences Issues Letter to Shareholders Exhibit 99.1 Guardion Health Sciences Issues Letter to Shareholders HOUSTON ? December 16, 2021 ? Guardion Health Sciences, Inc. (?Guardion? or the ?Company?) (Nasdaq: GHSI), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical devices, issued the following Letter to Shareholders: Dear Fellow Shareholders, I am delighted |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| December 9, 2021 |
Exhibit 99.1 Guardion Health Sciences Appoints Experienced Healthcare Executive Michaela Griggs to its Board of Directors HOUSTON ? December 9, 2021 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (Nasdaq: GHSI) (?Guardion? or the ?Company?), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical devices, announced today |
|
| December 8, 2021 |
Presentation dated December 2021 Exhibit 99.1 |
|
| December 8, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55723 GUARDION HEALTH |
|
| October 25, 2021 |
Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| October 22, 2021 |
Presentation dated October 2021 Exhibit 99.1 |
|
| October 22, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| September 23, 2021 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorpor |
|
| September 23, 2021 |
Exhibit 10.1 LEASE TERMINATION AGREEMENT This Lease Termination Agreement (the ?Agreement?) is entered into on September 22, 2021, by and between Cal-Sorrento, Ltd., a California limited partnership (the ?Landlord?) and Guardion Health Sciences, Inc., a Delaware corporation (the ?Tenant?, and collectively with Landlord, the ?Parties?). RECITALS A. Landlord and Tenant entered into that certain Indu |
|
| September 10, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorpor |
|
| September 10, 2021 |
Exhibit 99.1 |
|
| August 25, 2021 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] |
|
| August 24, 2021 |
Notice of Intention Not to Stand for Re-election Exhibit 17.1 |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporati |
|
| August 16, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporati |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55723 GUARDION HEALTH SCIEN |
|
| August 16, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months Ended June 30, 2021, including $1,000,000+ of Sales from Viactiv® Products in the First Month of Guardion’s Ownership Corporate Update and Overview of Growth Plans Also Provided HOUSTON, TEXAS – August 16, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or t |
|
| August 16, 2021 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made by and between Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?) and the individual identified on Exhibit A attached hereto (the ?Employee?) effective as of the Effective Date. RECITALS WHEREAS, the Company is a specialty health sciences company (i) that develops medical foods and medical de |
|
| August 10, 2021 |
Exhibit 99.1 ACTIV NUTRITIONAL, LLC Financial Statements As of December 31, 2020 and 2019 Independent Auditors? Report Those Charged with Governance Activ Nutritional, LLC, a subsidiary of Teal Acquisition Co., Inc.: Report on the Financial Statements We have audited the accompanying financial statements of Activ Nutritional, LLC, a subsidiary of Teal Acquisition Co., Inc., which comprise the bala |
|
| August 10, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 (June 1, 2021) GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdicti |
|
| August 10, 2021 |
GUARDION HEALTH SCIENCES, INC. Unaudited Condensed Combined Pro Forma Balance Sheet March 31, 2021 EX-99.2 4 ex99-2.htm Exhibit 99.2 GUARDION HEALTH SCIENCES, INC. Unaudited Condensed Combined Pro Forma Balance Sheet March 31, 2021 GHSI Activ Transaction Pro Forma March 31, 2021 March 31, 2021 Adjustments Combined Current assets Cash $ 43,329,674 $ 10 (26,044,582 )(a) $ 17,285,102 Accounts receivable 64,897 2,494,372 - 2,559,269 Inventories 288,527 603,776 - 892,303 Prepaid expenses 312,523 69, |
|
| August 10, 2021 |
GUARDION HEALTH SCIENCES, INC. Unaudited Condensed Combined Pro Forma Balance Sheet March 31, 2021 Exhibit 99.2 GUARDION HEALTH SCIENCES, INC. Unaudited Condensed Combined Pro Forma Balance Sheet March 31, 2021 GHSI Activ Transaction Pro Forma March 31, 2021 March 31, 2021 Adjustments Combined Current assets Cash $ 43,329,674 $ 10 (26,044,582 )(a) $ 17,285,102 Accounts receivable 64,897 2,494,372 - 2,559,269 Inventories 288,527 603,776 - 892,303 Prepaid expenses 312,523 69,284 363,000 (i) 744,8 |
|
| August 10, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 (June 1, 2021) GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdicti |
|
| August 10, 2021 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 ACTIV NUTRITIONAL, LLC Financial Statements As of December 31, 2020 and 2019 Independent Auditors’ Report Those Charged with Governance Activ Nutritional, LLC, a subsidiary of Teal Acquisition Co., Inc.: Report on the Financial Statements We have audited the accompanying financial statements of Activ Nutritional, LLC, a subsidiary of Teal Acquisition Co., Inc., wh |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation |
|
| August 2, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made by and between Guardion Health Sciences, Inc., a Delaware corporation (the ?Company?), and the individual identified on Exhibit A attached hereto (the ?Employee?) effective as of the Effective Date. RECITALS WHEREAS, the Company is a clinical nutrition and diagnostics company that develops clinically supported n |
|
| July 15, 2021 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdictio |
|
| June 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| June 9, 2021 |
PowerPoint Presentation, dated June 2021 Exhibit 99.1 |
|
| June 4, 2021 |
Exhibit 99.1 Guardion Health Sciences Broadens Clinical Nutrition Product Offerings by Closing Acquisition of Activ Nutritional, which owns the Science Backed, Revenue-Generating Viactiv? Product Line, from Adare Pharmaceuticals Acquisition to Transform and Strengthen Guardion?s Clinical Nutrition Product Portfolio Guardion Will Continue to Explore Additional Growth Opportunities to Further Expand |
|
| June 4, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 24, 2021 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction |
|
| May 21, 2021 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 47-4428421 (State or other jurisdiction of incorporation) |
|
| May 21, 2021 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EQUITY PURCHASE AGREEMENT made and entered into as of May 18, 2021 by and among GUARDION HEALTH SCIENCES, INC., ADARE PHARMACEUTICALS, INC. and ACTIV NUTRITIONAL, LLC THIS DOCUMENT IS INTENDED SOLELY TO FACILITATE DISCUSSIONS AMONG THE PARTIES REFERENCED HEREIN. IT IS NOT INTENDED TO, AND DOES NOT, CREATE A LEGALLY BINDING AGREEMENT OF ANY TYPE PRIOR TO THE DUE EX |
|
| May 21, 2021 |
Exhibit 99.1 Guardion Health Sciences to Acquire Activ Nutritional, LLC and Its Well-Known Viactiv? Brand of Products from Adare Pharmaceuticals, Inc. Acquisition to Transform and Strengthen Guardion?s Clinical Nutrition Product Portfolio Guardion Will Continue to Explore Additional Growth Opportunities to Further Expand its Presence in the Clinical Nutrition Market SAN DIEGO, May 18, 2021 (GLOBE |
|
| May 17, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporation) |
|
| May 17, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months Ended March 31, 2021 Company Provides Corporate Update and Overview of Growth Plans SAN DIEGO, CALIFORNIA – May 17, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically suppo |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55723 GUARDION HEALTH |
|
| May 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporation) |
|
| May 3, 2021 |
Exhibit 99.1 Guardion Health Sciences Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin? Product Clinical Trial Intended to Demonstrate Improved Visual Function in Glaucoma Patients Taking GlaucoCetin? SAN DIEGO ? May 3, 2021 (GLOBE NEWSWIRE) ? Guardion Health Sciences, Inc. (Nasdaq: GHSI) (?Guardion? or the ?Company?), a clinical nutrition and diagnostics company that |
|
| April 7, 2021 |
As filed with the U.S. Securities and Exchange Commission on April 6, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4428421 (State or other jurisdiction of incorporation or organizatio |
|
| March 26, 2021 |
Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months and Year Ended December 31, 2020 Company Provides Corporate Update and Overview of Growth Plans SAN DIEGO, CALIFORNIA – March 26, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops science-based, clinical |
|
| March 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporatio |
|
| March 26, 2021 |
EXHIBIT 21.1 LIST OF SUBSIDIARIES Name State or Other Jurisdiction of Incorporation VectorVision Ocular Health, Inc. Delaware Transcranial Doppler Solutions, Inc. Delaware NutriGuard Formulations, Inc. Delaware |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55723 GUARDION HEALTH SCIEN |
|
| March 26, 2021 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 25, 2021, Guardion Health Sciences, Inc. (?the Company?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?)?our common stock, par value $0.001 per share (?Common Stock?). Description |
|
| March 16, 2021 |
Presentation, dated March 2021 EX-99.2 3 ex99-2.htm Exhibit 99.2 |
|
| March 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporatio |
|
| March 16, 2021 |
Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule Exhibit 99.1 Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule SAN DIEGO – March 16, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutritional supplements, medical foods, and medical devices, announced that it has regained compliance wi |
|
| March 1, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT to CERTIFICATE OF INCORPORATION of GUARDION HEALTH SCIENCES, INC. GUARDION HEALTH SCIENCES, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify as follows: FIRST: The name of the Corporation is Guardion Health Sciences, Inc. The Certificate of Incorporation was filed with |
|
| March 1, 2021 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdi |
|
| March 1, 2021 |
Exhibit 99.1 Guardion Health Sciences Announces 1-for-6 Reverse Stock Split Effective Pre-Market Opening on Monday, March 1, 2021 Recent at-the-market financings and warrant exercises have netted a combined $37.2 million in 2021, providing an effective cash runway for program execution and acquisition strategy implementation SAN DIEGO, CALIFORNIA – February 26, 2021 (GLOBE NEWSWIRE) – Guardion Hea |
|
| February 12, 2021 |
SC 13G/A 1 ghsisc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities and Exchange Act of 1934 GUARDION HEALTH SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 4014Q203 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check th |
|
| January 28, 2021 |
Guardion Health Sciences, Inc. Up to $25,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248895 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 24, 2020) Guardion Health Sciences, Inc. Up to $25,000,000 Common Stock We have entered into an equity distribution agreement (the “Sales Agreement”) with Maxim Group LLC (“Maxim” or the “Distribution Agent”), dated January 8, 2021, relating to the sale of shares of our commo |
|
| January 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| January 27, 2021 |
Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdic |
|
| January 27, 2021 |
Exhibit 99.1 Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule SAN DIEGO, CALIFORNIA – January 27, 2021 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods, nutraceuticals and medic |
|
| January 8, 2021 |
EX-1.1 2 ex1-1.htm Exhibit 1.1 Guardion Health Sciences, Inc. Shares of Common Stock (par value $0.001 per share) Equity Distribution Agreement January 8, 2021 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 Ladies and Gentlemen: Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as sales agent, sh |
|
| January 8, 2021 |
Guardion Health Sciences, Inc. Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-248895 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 24, 2020) Guardion Health Sciences, Inc. $10,000,000 Common Stock We have entered into an equity distribution agreement (the “Sales Agreement”) with Maxim Group LLC (“Maxim” or the “Distribution Agent”), dated January 8, 2021, relating to the sale of shares of our common stoc |
|
| January 8, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporati |
|
| December 29, 2020 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and between Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), and the individual identified on Exhibit A attached hereto (the “Employee”), effective as of the Effective Date (as defined in Exhibit A). RECITALS WHEREAS, the Company is a publicly held and listed specia |
|
| December 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorpora |
|
| December 29, 2020 |
Exhibit 99.1 Guardion Health Sciences Appoints Seasoned Nutritional Products Industry Leader Bret Scholtes as President and Chief Executive Officer SAN DIEGO, CALIFORNIA – December 28, 2020 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nutrition, medical foods and medical device |
|
| December 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| November 13, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdi |
|
| November 13, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2020 Guardion Also Provides Corporate Update SAN DIEGO, CALIFORNIA – November 12, 2020 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a specialty health sciences company that develops clinically supported nu |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38861 GUARDION HEA |
|
| November 2, 2020 |
Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporat |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] |
|
| October 7, 2020 |
Guardion Provides Update on Strategy, Business Plans and Initiatives Exhibit 99.1 Guardion Provides Update on Strategy, Business Plans and Initiatives ● Emphasis on Differentiation of Brands and Development and Integration of E-Commerce Platform ● Further Development of Clinically Supported Nutritional Products and Continued Expansion into International Markets ● Retention of Corporate Finance Associates to Advise on Strategic Transactions Designed to Accelerate Co |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporati |
|
| September 23, 2020 |
Guardion Health Sciences, Inc. 15150 Avenue of Science, Suite 200 San Diego, California 92128 September 23, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Guardion Health Sciences, Inc. Registration Statement on Form S-3 File No. 333-248895 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Re |
|
| September 22, 2020 |
As filed with the Securities and Exchange Commission on September 22, 2020. Registration No. 333-248895 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-Effective Amendment No.1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4428421 (State or other juris |
|
| September 18, 2020 |
Exhibit 4.2 GUARDION HEALTH SCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES -1- TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 4 Section 1.1 Definitions of Terms 4 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 7 Section 2.1 Designation and Terms of Securities 7 Section 2.2 Form of Securities and Trustee’s Cert |
|
| September 18, 2020 |
As filed with the Securities and Exchange Commission on September 18, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4428421 (State or other jurisdiction (I.R.S. Employer of incorporat |
|
| September 18, 2020 |
Form of Subordinated Indenture Exhibit 4.3 GUARDION HEALTH SCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES -1- TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 4 Section 1.1 Definitions of Terms 4 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 7 Section 2.1 Designation and Terms of Securities 7 Section 2.2 Form of Securities and Trustee’ |
|
| September 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] |
|
| September 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorpora |
|
| August 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55723 GUARDION HEALTH S |
|
| August 12, 2020 |
Exhibit 99.1 Guardion Health Sciences Reports Results of Operations for Quarter Ended June 30, 2020 Asian Nutraceutical Sales Drive Second Quarter Revenues SAN DIEGO, California – August 12, 2020 – Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI), ), a specialty health sciences company that develops medical foods and medical devices in the ocular health space and nutrace |
|
| August 12, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporati |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] |
|
| July 23, 2020 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 Guardion Health Sciences Adds Experienced Vice President and Chief Financial Officer to Executive Management Team Newly-Appointed CFO Andrew Schmidt Brings Extensive and Wide-Ranging Public Company Experience San Diego, California – July 21, 2020 - Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced that it has appointed Andrew C. |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38861 44-4428421 (State or other jurisdiction of incorporation |
